Financials in USD. Standardized financial statements.
A compact view of how BioRestorative Therapies, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $359,700 | $401,000 | $145,800 | $119,800 | $46,000 | $77,000 | $130,000 | $111,000 | $81,000 | $36,355 |
| Revenue Growth? | -10.3% | +175.0% | +21.7% | +160.4% | -40.3% | -40.8% | +17.1% | +37.0% | +122.8% | 0.0% |
| Cost of Revenue? | $23,844 | $28,072 | $0 | $0 | $0 | $0 | $0 | $0 | $259,260 | $102 |
| Gross Profit? | $335,856 | $372,928 | $145,800 | $119,800 | $46,000 | $77,000 | $130,000 | $111,000 | -$178,260 | $36,253 |
| Gross Margin? | +93.4% | +93.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | -220.1% | +99.7% |
| Operating Expenses? | $15.98M | $11.93M | $15.37M | $18.98M | $26.35M | $2.83M | $8.56M | $7.76M | $8.46M | $7.83M |
| Operating Income? | -$15.65M | -$11.56M | -$15.22M | -$18.86M | -$26.31M | -$2.75M | -$8.43M | -$7.65M | -$8.37M | -$7.80M |
| EBITDA? | -$15.44M | -$11.37M | -$14.97M | -$18.74M | -$26.22M | -$9.48M | -$9.29M | -$9.06M | -$8.10M | -$7.61M |
| Income Before Tax | -$14.24M | -$8.98M | -$10.42M | -$13.22M | -$44.30M | -$11.27M | -$14.65M | -$12.52M | -$9.44M | -$8.64M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$14.24M | -$8.98M | -$10.42M | -$13.22M | -$44.30M | -$11.27M | -$14.65M | -$12.52M | -$9.44M | -$8.64M |
| EPS? | $-1.58 | $-1.16 | $-2.47 | $-3.65 | $-37.30 | $-28.56 | $-3217.82 | $-4269.37 | $-6181.06 | $-7356.30 |
| Diluted EPS? | $-1.58 | $-1.16 | $-2.47 | $-3.65 | $-37.30 | $-28.56 | $-3217.82 | $-4269.37 | $-6181.06 | $-7356.30 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality